Scholar Rock Holding (SRRK) Capital Expenditures (2017 - 2026)
Scholar Rock Holding's (SRRK) quarterly Capital Expenditures came in at $37000.0 in Q1 2026, down 86.35% year-on-year from $271000.0 in Q1 2025, and up 15.62% quarter-over-quarter from $32000.0 in Q4 2025.
Scholar Rock Holding (SRRK) Capital Expenditures (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Capital Expenditures history runs 10 years deep, the most recent figure standing at $37000.0 for Q1 2026.
- On a quarterly basis, Capital Expenditures fell 86.35% year-over-year to $37000.0 in Q1 2026; TTM through Mar 2026 was $368000.0, a 46.2% decrease from a year earlier, with the FY2025 full-year figure at $602000.0, up 514.29% from the prior year.
- Capital Expenditures advanced to $37000.0 in Q1 2026 per SRRK's latest filing, from $32000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $3.1 million in Q4 2023 and bottomed at -$653000.0 in Q3 2024.
- The 5-year median for Capital Expenditures is $37000.0 (2026), against an average of $264647.1.
- Biggest YoY gain for Capital Expenditures was 344.9% in 2024; the steepest drop was 1150.0% in 2024.
- Year by year, Capital Expenditures stood at $952000.0 in 2022, then jumped by 224.05% to $3.1 million in 2023, then sank by 77.12% to $706000.0 in 2024, then slumped by 95.47% to $32000.0 in 2025, then grew by 15.62% to $37000.0 in 2026.
- Per Business Quant, the three latest SRRK Capital Expenditures figures stand at $37000.0 (Q1 2026), $32000.0 (Q4 2025), and $551000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 43.25 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 786,000.00 |
| 10 | Scholar Rock Holding | 6.32 Bn | 6.32 Bn | - | 37,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37,000.00 |
| Mar 31, 2026 | 37,000.00 |
| Dec 31, 2025 | 32,000.00 |
| Dec 31, 2025 | 32,000.00 |
| Sep 30, 2025 | 551,000.00 |
| Sep 30, 2025 | 551,000.00 |
| Jun 30, 2025 | -252,000.00 |
| Jun 30, 2025 | -252,000.00 |
| Mar 31, 2025 | 271,000.00 |
| Mar 31, 2025 | 271,000.00 |
| Dec 31, 2024 | 706,000.00 |
| Dec 31, 2024 | 706,000.00 |
| Sep 30, 2024 | -653,000.00 |
| Sep 30, 2024 | -653,000.00 |
| Jun 30, 2024 | 360,000.00 |
| Jun 30, 2024 | 360,000.00 |
| Mar 31, 2024 | -315,000.00 |
| Mar 31, 2024 | -315,000.00 |
| Dec 31, 2023 | 3.09 Mn |
| Dec 31, 2023 | 3.09 Mn |